Compare Mesoblast Limited (MESO) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? Mesoblast Limited trades at $16.38 (market cap $2.17B), while Vanguard S&P 500 Growth Index Fund ETF trades at $81.98. The key difference: Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | VOOG | |
|---|---|---|
Market Cap | $2.17B | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $20.96 | $85.11 |
52-Week Low | $12.88 | $65.32 |
Enterprise Value | $2.17B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.63, down 3.98% today, with a bullish technical signal from moving averages. The company reported Q2 2026 revenue of $36 million for Ryoncil, showing strong commercial progress, but maintains a net income margin of -144.33% with significant losses. Recent news highlights pivotal Phase 3 trial milestones for chronic low back pain treatment and a $50 million non-dilutive financing draw.
Outlook is mixed: bullish analyst sentiment and clinical advancements offer upside potential, but high cash burn and persistent losses pose substantial risks. Investors should weigh the company's growth trajectory against its financial sustainability and regulatory milestones.
VOOG (Vanguard S&P 500 Growth ETF) trades at $80.98, up 0.28% with a bearish technical signal from moving averages. The ETF provides exposure to 212 large-cap growth stocks with a 0.07% expense ratio and heavy technology sector concentration. Recent news highlights comparisons with other growth ETFs, noting VOOG's strong long-term performance and competitive fee structure.
The outlook remains cautious due to bearish technical indicators and concentrated tech exposure, though the low expense ratio and S&P 500 growth focus provide structural advantages. Key risks include tech sector volatility and market sentiment shifts, while institutional interest remains steady given Vanguard's reputation and the ETF's track record.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
